The Study of Pharmacological Efficacy in Dry Mulberry Burirum-60 in MildStage of Alzheimer's Disease

Buavaroon Srichaikul

Abstract


Alzheimer’s Disease is a condition in which occurs in the area concerning the deteriation of brain function. This condition of disease is not completely curative treatment by medicines and always happens in the eldery with ages over 55 years old. However it can delay and maintain the condition of the stages of deteriation of brain function. In this experiment. We used Morus alba Linn. Burirum 60 leaves collected from Mahasarakham University Research Plantation Field, the Division of Research Innovation and were prepared as a powder in capsule form to control the incidence and maintain brain function condition in Mild stage of Alzheimer’s disease patients. Morus alba Linn. contains many minerals and vitamin A, vitamin B, vitamin B3, vitamin B12, vitamin C, essential amino acids, Zinc, Magnesium, Sodium, deoxynojirimycin, GABA, Phytosterol , Calcium, Potassium, folic acid etc.. The samples of this research were collected from silk weaving women, ages of 55-70 years old in Silk Innovation Weaving Village, supported by Mahasarakham University. The samples were divided into 4 groups as follows: group no.1 of feeding silkworms weaving women and intake Morus alba Burirum 60 capsule, group no.2 of feeding silkworms weaving women  and intake placebo, group no.3 of non feeding silkworm weaving women and intake Morus alba Burirum 60 capsule, group no.4 of non feeding silkworms weaving women and intake the placebo. All samples were tested with Cognitive Testing Scale and the selected samples were Mild cognitive memory function group. The dosage of Morus alba capsule would have 2 capsules after meals , once daily for 3 months and all the samples were tested for cognitive memory function using the scales of Sage1, Mini-Mental state Examination (MMSE), Functional Assessment Stage tool (Fast) for evaluation and confirmation of the efficacy of Mulberry (Morus alba Burirum 60) effecting the brain function. The data were tested with Wilcoxon Signed Rank Test and Kruskal Wallis statistical analysis. The result revealed that each 4 groups of Group no.1, no.2, no.3, and no.4 were 3.00, 1.50, 3.00 and 2.00 respectively. It showed that in each group had indicated mean scores with statistical significant difference at p-value 0.05. It showed the development of changing scores tested by SAGE1 scale within the group. Then we compared the mean scores difference among or in between groups by using the Kruskal Wallis statistical method. The result found that the mean rank score among 4 groups before the experiment were 14.10, 12.70, 7.30 and 7.90 respectively and the mean rank score among 4 groups after the experiment were 17.70, 8.70, 11.00 and 4.60 respectively. The higher rank of each groups indicated the higher development in obtaining the scores of SAGE1 tested by Kruskal Wallis after the experiment by oral intake of Morus alba Linn. Burirum-60 capsules with the dosage of 200 mg daily for 3 months. It showed the development of cognitive memory function by increasing the ranking scores of group no.1, group no.3 and group no.2 respectively. The suggestion of this study for the future research is to increase the size of samples and clinical confirmed with CT-SCAN or NMR in order to measure the comparison of improvement in the density and brain image before and after the experiment and also the duration of administering or intake Morus alba Linn. Burirum-60 should be recommended to extend longer period of time and may be increase in the daily dosage.  
Key words: Mild cognitive memory impairment; MMSE; SAGE1; FAST; Alzheimer Disease

Keywords


Mild cognitive memory impairment; MMSE; SAGE1; FAST; Alzheimer Disease

References


Akhondzadeh S., Noroozian M., Mohammadi M., Ohadinia S., Jamshidi A.H. & Khani M. (2003). Salvia Officinalis Extract in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease: A Double Blind, Randomized and Placebo-Controlled Trial. J. Clin. Pharm. Ther., 28(1), 53-59.

Auer S. R., Sclan S. G., Yaffee R. A., & Reisberg B. (1994). The Neglected Half of Alzheimer Disease: Cognitive and Functional Concomitants of Severe Dementia. J. Am. Geriatr. Soc., 42, 1266-1272.

Bobinski, M., Wegiel, J., Tarnawski, M., Bobinski, M., Reisberg, B., de Leon, M. J., Miller, D. C., & Wisniewski, H. M. (1997). Relationships Between Regional Neuronal Loss and Neurofibrillary Changes in the Hippocampal Formation and Duration and Severity of Alzheimer Disease. J. Neuropathol Exp. Neurol., 56, 414-420.

De Marco, B. (2008). Simple Pen-and-Paper Alzheimer’s Memory Test is Important News (SAGE). Retreived from http://www.wellsphere.com/caregiving-article/simple-pen-and-paper-alzheimer-s-memory-test-is-important-news-sage/1069041

De Marco, B. (2010). Test Your Memory for Alzheimer’s Dementia in 15 Minutes (SAGE). Retreived from alzheimersreadingroom.com

Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini-mental State: A Practical Method for Grading the Cognitive State of Patients for the Clinician. J. Psychiatr. Res., 12, 189-198.

Mayeux, R. (2010). Early Alzheimer’s Disease. N. Engl. J. Med., 362(4), 2194-2201.

Querfurth, H.W., & LaFerla, F. M. (2010). Alzheimer’s Disease. N. Engl. J. Med., 362(4), 329-344.

Reisberg, B. (1988). Functional Assessment Staging (FAST). Psychopharmacology Bulletin, 24, 653-659.

Reisberg, B., Ferris, S. H., de Leon, M. J., & Crook, T. (1982). The Global Deterioration Scale for Assessment of Primary Degenerative Dementia. Am. J. Psychiatry., 139, 1136-1139.

Venkatesh Kumar, R., & Chauhan, S. (2008). Mulberry: Life Enhancer. Journal of Medicinal Plants Research, 2(10), 271-278.




DOI: http://dx.doi.org/10.3968%2Fj.ans.1715787020120502.1325

Refbacks

  • There are currently no refbacks.


Reminder

If you have already registered in Journal A and plan to submit article(s) to Journal B, please click the CATEGORIES, or JOURNALS A-Z on the right side of the "HOME".

We only use the following emails to deal with issues about paper acceptance, payment and submission of electronic versions of our journals to databases:
caooc@hotmail.com; office@cscanada.net; office@cscanada.org
ans@cscanada.net;ans@cscanada.org

Copyright © Canadian Research & Development Centre of Sciences and Cultures (CRDCSC)
Address:730, 77e AV, Laval, Quebec, H7V 4A8, Canada

Telephone: 1-514-558 6138
Http://www.cscanada.net; Http://www.cscanada.org
E-mail:caooc@hotmail.com; office@cscanada.net